- Home
- MLYS vs VINP Comparison
MLYS vs VINP Comparison
Compare MLYS & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- VINP
- Stock Information
- Founded
- MLYS 2019
- VINP 2009
- Country
- MLYS United States
- VINP Brazil
- Employees
- MLYS N/A
- VINP N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- VINP Investment Managers
- Sector
- MLYS Health Care
- VINP Finance
- Exchange
- MLYS Nasdaq
- VINP Nasdaq
- Market Cap
- MLYS 634.6M
- VINP 641.7M
- IPO Year
- MLYS 2023
- VINP 2021
- Fundamental
- Price
- MLYS $9.77
- VINP $9.91
- Analyst Decision
- MLYS Strong Buy
- VINP Strong Buy
- Analyst Count
- MLYS 2
- VINP 2
- Target Price
- MLYS $30.00
- VINP $13.50
- AVG Volume (30 Days)
- MLYS 266.6K
- VINP 95.1K
- Earning Date
- MLYS 11-11-2024
- VINP 02-05-2025
- Dividend Yield
- MLYS N/A
- VINP 6.46%
- EPS Growth
- MLYS N/A
- VINP N/A
- EPS
- MLYS N/A
- VINP 0.60
- Revenue
- MLYS N/A
- VINP $88,217,697.00
- Revenue This Year
- MLYS N/A
- VINP $17.23
- Revenue Next Year
- MLYS N/A
- VINP $51.06
- P/E Ratio
- MLYS N/A
- VINP $16.57
- Revenue Growth
- MLYS N/A
- VINP 9.03
- 52 Week Low
- MLYS $8.58
- VINP $9.01
- 52 Week High
- MLYS $16.91
- VINP $11.85
- Technical
- Relative Strength Index (RSI)
- MLYS 37.52
- VINP 50.15
- Support Level
- MLYS $9.18
- VINP $9.61
- Resistance Level
- MLYS $9.97
- VINP $10.14
- Average True Range (ATR)
- MLYS 0.85
- VINP 0.24
- MACD
- MLYS -0.25
- VINP 0.02
- Stochastic Oscillator
- MLYS 24.53
- VINP 75.79
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.